imported>David Gerard at 19:33, 31 August 2021

2021-08-31T19:33:10Z

New page

{{Use dmy dates|date=June 2018}}
{{Use Indian English|date=June 2018}}

'''Intas Biopharmaceuticals Ltd''' is an [[India|Indian]] [[Multinational corporation|multinational]] [[Corporation|company]] headquartered in [[Ahmedabad, India|Ahmedabad]], [[Gujarat]]. It was founded by Dr. Urmish Chudgar and is now headed by Hasmukh Chudgar. The Biologics unit (BU) of the company is located in [[Ahmedabad]] and it is one of the leading [[biosimilar]] product manufacturers in [[Asia]]. The unit (BU) has its own biopharmaceutical operations with a R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.<ref>{{cite news |title=Intas mfg unit gets EU-GMP certification| date= 13 June 2007 | publisher= The Economic Times|url=http://economictimes.indiatimes.com/News/News_By_Industry/Healthcare__Biotech/Biotech/Intas_mfg_unit_gets_EU-GMP_certification/rssarticleshow/2118921.cms}}</ref>{{Infobox company
| name = Intas Biopharmaceuticals
| logo = Intasbio logo.png
| logo_caption = Logo of Intas Biopharmacueticals
| image = Intas Biopharmacueticals.jpg
| image_caption = Headquarters of Intas Biopharmaceuticals
| type = [[Private company|Private]]
| foundation = {{Start date and age|1984}}
| founder = Dr. Urmish Chudgar
| location = [[Ahmedabad]], [[Gujarat]]
| hq_location_country = [[India]]
| industry = [[Biopharmaceuticals]]
| area_served = Worldwide
| products = Neukine (GCSF) Erykine (EPO) Intalfa (IFN) Pegasta (Peg GCSF) Terifrac (Teriparatide) Mabtas (Rituximab) Folisurge (FSH)
| revenue = {{up}} [[₹]] 12,600 [[crore]] ([[US$]] 1.8 Billion)
| revenue_year = 2019
| net_income = {{up}} [[₹]] 1,248 [[crore]] ([[US$]] 204 [[Million]])
| net_income_year = 2019
| num_employees = 8000+
| num_employees_year = 2021
| homepage = {{URL|https://www.intaspharma.com/}}
}}

== History ==
Intas Biopharmaceuticals Limited was set up in 1980 by Dr. Urmish Chudgar, a [[Hematology|hematologist]], as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Hasmukh Chudgar.

== Present ==
The company faced an EU-GMP ([[Good Manufacturing Practice]]) audit in December 2006, to seek approval for a clinical trial of its [[biosimilar]] [[Filgrastim]] in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.<ref>{{Cite news|title=Intas mfg unit gets EU-GMP certification|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/intas-mfg-unit-gets-eu-gmp-certification/articleshow/2118921.cms?from=mdr|access-date=2021-07-04}}</ref>

Apart from EU-GMP certification, the company has approvals from MCC [[South Africa]], [[Gulf Cooperation Council]] (GCC), [[Syria]], [[Yemen]], [[Belarus]] and several other national health authorities for its manufacturing facility and products.<ref>{{Cite web|title=About Us – Intas Pharmaceuticals Ltd.|url=https://www.intaspharma.com/about-us/|access-date=2021-07-04|language=en-US}}</ref><ref>{{Cite web|date=2015-01-23|title=Intas's Growth Driver : Biopharmaceuticals|url=https://nckpharma.com/intas-growth-driver-biopharmaceuticals/|access-date=2021-07-04|website=NCK Pharma|language=en-US}}</ref>

== Products ==
In 2015, the company launched Accofil, a treatment for immune system disorders.<ref>{{cite web|author=|date=23 February 2015|title=Intas Pharma launches its first biosimilar product Accofil in Europe|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-pharma-launches-its-first-biosimilar-product-accofil-in-europe/articleshow/46342034.cms|access-date=25 April 2019|publisher=|via=The Economic Times}}</ref><ref>{{cite web|last=Reporter|first=B. S.|date=23 February 2015|title=Ahmedabad-based Intas Pharma launches biosimilar in EU|url=https://www.business-standard.com/article/companies/ahmedabad-based-intas-pharma-launches-biosimilar-in-eu-115022300721_1.html|access-date=25 April 2019|publisher=|via=Business Standard}}</ref>

{{Gallery|Rituximab ( MabTas ).jpg|MabTas is Rituximab biosimilar of Intas|Accofil.JPG|Intas manufactured Filgrastim (Accofil) registered in EU|title=Products of Intas Biopharmaceuticals and timeline|width=160|height=170|align=center|Intas product development timeline.png|Intas Biosimilar development timeline}}

== Financials ==
The company had an annual revenue of $1.8 [[Billion]] (₹12,600 [[crore]]) in 2019 and a profit of $204 [[1,000,000|Million]] (₹1,248 crore) after taxes in the financial year 2019. The company's 69% of revenue came from international operations in the FY2019 while just 31% came from [[India]].<ref>{{Cite web|title=Financials – Intas Pharmaceuticals Ltd.|url=https://www.intaspharma.com/financials/|access-date=2021-07-04|language=en-US}}</ref>

== Acquisitions ==

* In 2016, Intas acquired the assets of [[Teva Pharmaceuticals]] in the [[United Kingdom|UK]] and [[Ireland]] for [[Dollar sign|$]]764 million.<ref>{{Cite news|last=Dandekar|first=Vikas|last2=Barman|first2=Arijit|date=2016-10-06|title=Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-buys-tevas-uk-ireland-assets-for-764-million-to-break-into-global-top-20-generic-players-club/articleshow/54696609.cms?from=mdr|access-date=2020-05-08}}</ref><ref>{{cite web|last1=Dandekar|first1=Vikas|last2=Barman|first2=Arijit|date=7 October 2016|title=Chudgars of Intas: A family that dreams big together|url=https://economictimes.indiatimes.com/news/company/corporate-trends/chudgars-of-intas-a-family-that-dreams-big-together/articleshow/54725284.cms|access-date=25 April 2019|publisher=|via=The Economic Times}}</ref>
* In 2017, the company announced acquisition of [[Actavis|Actavis UK Ltd.]] & [[Actavis|Actavis Ireland Ltd]] from [[Teva Pharmaceuticals|Teva Pharmaceutical Industries]], for an enterprise value of [[Pound sterling|£]]603 million.<ref>{{Cite web|title=Intas Pharmaceuticals Completes Deal to Acquire Actavis|url=https://www.moneycontrol.com/news/business/companies/intas-pharmaceuticals-completes-deal-to-acquire-actavis-941493.html|access-date=2020-05-08|website=Moneycontrol}}</ref><ref>{{Cite web|last=Bureau|first=Our|title=Intas to acquire UK & Ireland generics businesses from Teva for £603 million|url=https://www.thehindubusinessline.com/companies/intas-to-acquire-uk-amp-ireland-generics-businesses-from-teva-for-603-million/article21712880.ece|access-date=2021-07-04|website=@businessline|language=en}}</ref>
== References ==
{{Reflist}}

== External Links ==
[https://www.intaspharma.com/ Official site]
[[Category:Indian brands]]
[[Category:Pharmaceutical companies of India]]
[[Category:Biotechnology companies of India]]
[[Category:Pharmaceutical companies established in 2000]]
[[Category:Manufacturing companies based in Ahmedabad]]
[[Category:Biotechnology companies established in 2000]]
[[Category:2000 establishments in Gujarat]]

Intas Biopharmaceuticals - Revision history

imported>David Gerard at 19:33, 31 August 2021